CCL25 and neoplasm: In the study, NP-siCD47/CCL25 remarkably increased the invasiveness of CCR9+CD8+ T cells, inhibited the expression of CD47 in tumor cells, and inhibited tumor cells metastasis and growth by T-cell-dependent immunity (Chen et al., 2020).